(Q43869854)

27 November 2017

Depo-provera associated with weight gain in Navajo women (English)

1 reference

medroxyprogesterone acetate

27 November 2017

1 reference

1 reference

Espey E

1

1 reference

27 November 2017

Steinhart J

series ordinal

2

1 reference

27 November 2017

Ogburn T

series ordinal

3

1 reference

27 November 2017

Qualls C

series ordinal

4

1 reference

27 November 2017

language of work or name

1 reference

1 August 2000

1 reference

27 November 2017

1 reference

27 November 2017

62

1 reference

27 November 2017

2

1 reference

27 November 2017

55-58

1 reference

Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Contraceptive use among adolescent mothers at 6 months postpartum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Effect of long-term hormonal contraception on plasma lipids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Experiences of injectable contraceptive users in an urban setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2800%2900144-X

10.1016/S0010-7824(00)00144-X

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference